A phase 1/2, open-label study to evaluate the safety and efficacy of autologous CD19-specific chimeric antigen receptor T cells (CABA-201) in subjects with active idiopathic inflammatory myopathy or active juvenile idiopathic inflammatory myopathy

Disease:

Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy, Juvenile Dermatomyositis, Juvenile Polymyositis, Juvenile Idiopathic Inflammatory Myopathy (JIIM), Juvenile Myositis

Study phase:

Physician name:

Huifang (Linda) Lu

Department:

General Internal Medicine

For general questions about clinical trials:

1-844-514-2993